PT  - JOURNAL ARTICLE
AU  - Bünger, Isabel
AU  - Makridis, Konstantin L.
AU  - Kreye, Jakob
AU  - Nikolaus, Marc
AU  - Sedlin, Eva
AU  - Ullrich, Tim
AU  - Rasmussen, Helle Foverskov
AU  - Milovanovic, Dragomir
AU  - Hoffmann, Christian
AU  - Tromm, Johannes
AU  - Höltje, Markus
AU  - Prüss, Harald
AU  - Kaindl, Angela M.
TI  - Maternal synapsin 1 autoantibodies are associated with neurodevelopmental delay
AID  - 10.1101/2022.11.17.22282130
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.11.17.22282130
4099  - http://medrxiv.org/content/early/2022/11/18/2022.11.17.22282130.short
4100  - http://medrxiv.org/content/early/2022/11/18/2022.11.17.22282130.full
AB  - Maternal autoantibodies can be transmitted diaplacentally, with potentially deleterious effects on neurodevelopment. Synapsin 1 (SYN1) is a neuronal protein that is important for synaptic communication and neuronal plasticity. While monoallelic loss of function (LoF) variants in the SYN1 gene result in X-linked intellectual disability (ID), learning disabilities, epilepsy, behavioral problems, and macrocephaly, the effect of SYN1 autoantibodies on neurodevelopment remains unclear. We recruited a clinical cohort of 208 mothers and their children with neurologic abnormalities and analyzed the role of maternal SYN1 autoantibodies. We identified seropositivity in 9.6% of mothers, and seropositivity was associated with an increased risk for ID and behavioral problems. Furthermore, children more frequently had epilepsy, macrocephaly, and developmental delay, in line with the SYN1 LoF phenotype. Whether SYN1 autoantibodies have a direct pathogenic effect on neurodevelopment or serve as biomarkers requires functional experiments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the German Research Foundation (DFG) (grants FOR3004, PR1274/4-1, PR1274/5-1, PR1274/9-1), by the Helmholtz Association (HIL-A03), the German Federal Ministry of Education and Research (Connect-Generate 01GM1908D), the Einstein Stiftung Fellowship through the Guenter Endres Fond, and the Sonnenfeld-Stiftung.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of Charite - Universitatsmedizin Berlin (approval no. EA2/220/20).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.